Literature DB >> 34219769

Diseases associated with hypercobalaminemia in dogs in United Kingdom: A retrospective study of 47 dogs.

Fiona Da Riz1, Paul Higgs1, Guillaume Ruiz1.   

Abstract

Cobalamin concentration is often assessed in clinical practice but little is known about the significance of hypercobalaminemia. The objective of this retrospective study was to identify the conditions associated with hypercobalaminemia in dogs and to investigate association with clinicopathological variables. Medical records of dogs having serum cobalamin measured between 2016 and 2018 were reviewed. One hundred sixty dogs were included and 47 (29%) showed hypercobalaminemia. Dogs with hypercobalaminemia had gastrointestinal (57%), hepatic (11%), neurological (11%), endocrine (9%), renal (4%), pancreatic (2%), and miscellaneous (6%) diseases. Overall, 11% had neoplasia. This distribution was not significantly different from that for hypocobalaminemic and normocobalaminemic dogs. There were significantly more dogs with hyperfolatemia in the hypercobalaminemia group. These results suggest that in clinical practice hypercobalaminemia is commonly identified in gastrointestinal and hepatic disease in dogs, but can also be seen with endocrine and neurological conditions. The frequency of hyperfolatemia alongside hypercobalaminemia may reflect common metabolic pathways. Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.

Entities:  

Year:  2021        PMID: 34219769      PMCID: PMC8118170     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  21 in total

Review 1.  Antibiotic-responsive diarrhea in small animals.

Authors:  Edward J Hall
Journal:  Vet Clin North Am Small Anim Pract       Date:  2011-03       Impact factor: 2.093

2.  Effect of age, sex and body weight on the serum concentrations of cobalamin and folate in cats consuming a consistent diet.

Authors:  Sarah A Hill; Nicholas J Cave; Sandra Forsyth
Journal:  J Feline Med Surg       Date:  2017-03-22       Impact factor: 2.015

3.  Serum cobalamin and methylmalonic acid concentrations in dogs with chronic gastrointestinal disease.

Authors:  Nora Berghoff; Nolie K Parnell; Steve L Hill; Jan S Suchodolski; Jörg M Steiner
Journal:  Am J Vet Res       Date:  2013-01       Impact factor: 1.156

4.  Analytical quality assessment and method comparison of immunoassays for the measurement of serum cobalamin and folate in dogs and cats.

Authors:  Susan A McLeish; Kay Burt; Kostas Papasouliotis
Journal:  J Vet Diagn Invest       Date:  2019-01-13       Impact factor: 1.279

Review 5.  Vitamin B12 as a modulator of gut microbial ecology.

Authors:  Patrick H Degnan; Michiko E Taga; Andrew L Goodman
Journal:  Cell Metab       Date:  2014-11-04       Impact factor: 27.287

6.  Small intestinal bacterial overgrowth in dogs with chronic intestinal disease.

Authors:  H C Rutgers; R M Batt; C M Elwood; A Lamport
Journal:  J Am Vet Med Assoc       Date:  1995-01-15       Impact factor: 1.936

7.  Chronic enteropathies in dogs: evaluation of risk factors for negative outcome.

Authors:  K Allenspach; B Wieland; A Gröne; F Gaschen
Journal:  J Vet Intern Med       Date:  2007 Jul-Aug       Impact factor: 3.333

8.  Vitamin B12 binding protein as a tumour marker for hepatocellular carcinoma.

Authors:  S P Kane; I M Murray-Lyon; F J Paradinas; P J Johnson; R Williams; A H Orr; J Kohn
Journal:  Gut       Date:  1978-12       Impact factor: 23.059

9.  Cobalamin related parameters and disease patterns in patients with increased serum cobalamin levels.

Authors:  Johan F B Arendt; Ebba Nexo
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

10.  Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies.

Authors:  Romy M Heilmann; Nora Berghoff; Joanne Mansell; Niels Grützner; Nolie K Parnell; Corinne Gurtner; Jan S Suchodolski; Jörg M Steiner
Journal:  J Vet Intern Med       Date:  2018-02-20       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.